News from merrimack pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 29, 2007, 00:00 ET

Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors

CAMBRIDGE, Mass., Nov. 29 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Jul 23, 2007, 01:00 ET

Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer

CAMBRIDGE, Mass., July 23 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Jun 26, 2007, 01:00 ET

Merrimack Pharmaceuticals Names Lisa Evren Senior Vice President and Chief Financial Officer

CAMBRIDGE, Mass., June 26 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Jun 12, 2007, 01:00 ET

Merrimack Pharmaceuticals Receives U.S. Patent Covering Composition of Matter for Recombinant, Non-Glycosylated Human Alpha-fetoprotein; Extends Patent Protection of Lead Product, MM-093, into 2025

CAMBRIDGE, Mass., June 12 /PRNewswire/ -- Merrimack Pharmaceuticals announced today the issuance of a patent from the United States Patent and...

Apr 17, 2007, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., April 17 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 study to evaluate the...

Apr 04, 2007, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis

CAMBRIDGE, Mass., April 4 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 pilot study to determine...

Jul 17, 2006, 01:00 ET

Merrimack Pharmaceuticals Announces the Addition of Louis Weiner, M.D., to its Scientific Advisory Board

CAMBRIDGE, Mass., July 17 /PRNewswire/ -- Merrimack Pharmaceuticals today announced the addition of Louis Weiner, M.D., to its Scientific...

May 15, 2006, 01:00 ET

Merrimack Pharmaceuticals Announces Two Additions to its Board of Directors

CAMBRIDGE, Mass., May 15 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

May 03, 2006, 01:00 ET

Merrimack Pharmaceuticals Names Fazal Khan, Ph.D., Vice President of Manufacturing

CAMBRIDGE, Mass., May 3 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Apr 19, 2006, 01:00 ET

Merrimack Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093 In Patients With Psoriasis

CAMBRIDGE, Mass., April 19 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the completion of enrollment of 27 patients into a...

Apr 03, 2006, 01:00 ET

Merrimack Pharmaceuticals Raises $65 Million in Private Financing

CAMBRIDGE, Mass., April 3 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of...

Feb 28, 2006, 00:00 ET

Merrimack Pharmaceuticals Announces the Addition of Barrett Rollins, MD, PhD to its Scientific Advisory Board

CAMBRIDGE, Mass., Feb. 28 /PRNewswire-FirstCall/ -- Barrett Rollins, M.D., Ph.D. has joined the Scientific Advisory Board (SAB) of Merrimack...

Oct 19, 2005, 01:00 ET

Merrimack Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093 in Patients With Rheumatoid Arthritis

CAMBRIDGE, Mass., Oct. 19 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the completion of enrollment of 258 patients into a...

Oct 13, 2005, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Psoriasis

CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2a pilot study of the safety...

May 24, 2005, 01:00 ET

Merrimack Pharmaceuticals Announces the Addition of Two New Members to its Scientific Advisory Board

CAMBRIDGE, Mass., May 24 /PRNewswire/ -- Dan R. Littman, M.D., Ph.D. and James D. Marks, M.D., Ph.D have joined the Scientific Advisory Board...

May 03, 2005, 01:00 ET

Merrimack Pharmaceuticals Appoints Gary L. Crocker as Chairman of the Board

CAMBRIDGE, Mass., May 3 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of...

Apr 20, 2005, 01:00 ET

Merrimack Pharmaceuticals Closes on $37 Million of Series D Equity and Loan Financing

CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that it has completed equity and debt financings...

Mar 03, 2005, 00:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., March 3 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 study of the safety and...

Aug 25, 2004, 01:00 ET

Merrimack Pharmaceuticals Completes Enrollment for Phase IIa Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the completion of enrollment for a Phase IIa pilot...

Jul 20, 2004, 01:00 ET

Merrimack Pharmaceuticals Names Dr. Brian L. Hamilton Vice President of Clinical and Regulatory Affairs

CAMBRIDGE, Mass., July 20 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that Brian L. Hamilton, M.D., Ph.D., has joined the...